Court Won’t Toss Suit Against Regeneron Over Alleged Fraud In Vision Drug Pricing

( April 30, 2025, 2:55 PM EDT) -- BOSTON — A Massachusetts federal judge on April 29 denied dismissal of a qui tam suit against Regeneron Pharmaceuticals Inc. alleging violations of the federal False Claims Act (FCA) and similar state laws for purportedly fraudulently reporting the average sales price of a drug used to treat age-related vision impairment, finding that “the allegations sufficiently establish falsity under the FCA.”...

Attached Documents

Related Sections